Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT02953743 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Lenvatinib

Sponsor

Eisai Co., Ltd.